- Home
- Funding Opportunities
- Advisory Boards
- President's Cancer Panel
- National Cancer Advisory Board
- Board of Scientific Advisors
- Board of Scientific Counselors - Basic Sciences
- Board of Scientific Counselors - Clinical Sciences and Epidemiology
- Clinical Trials and Translational Research Advisory Committee
- NCI Council of Research Advocates
- Frederick National Laboratory Advisory Committee
- NCI Initial Review Groups
- Special Emphasis Panel
- Office of Federal Advisory Committee Policy
- Board Presentations
- Grant Policies
- Consumer Advocates
- NCI Consumer Guide to Peer Review
The NCI Consumer Guide to Peer Review has been prepared to serve first as an introduction and orientation to the National Cancer Institute (NCI) and its Research Programs and second to define your role as a consumer in the Peer Review of applications that support extramural clinical/population-based research conducted by Cancer Centers, Cooperative Groups, Program Projects, and projects submitted in response to Requests for Applications (RFAs) and Program Announcements (PAs). - Cancer Dictionary for Peer Review
Cancer Dictionary for Peer Review is deigned to provide concise definitions of technical terms frequently used in applications for NCI-sponsored investigator-initiated research. The terms include those commonly associated with the molecular biology of cancer, immunology, and clinical oncology. These definitions, in association with the review process, will increase your familiarity and understanding of the biology and clinical aspects of cancer. We hope this will facilitate and make your participation in the Peer Review process more meaningful. - Office of Advocacy Relations
- NCI Council of Research Advocates
- NCI Consumer Guide to Peer Review
- Awarded Research
About DEA (Division of Extramural Activities) |
---|
The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the NCI and the scientific community with expert scientific review of the merits of extramural research, procedures, and policies to help the Institute achieve its goal. An important part of DEA’s mission is to manage and coordinate the second level of grants review with the National Cancer Advisory Board and the concept review of all new and reissued Request for Applications (RFAs) and research and development (R&D;) Request for Proposals (RFPs) with the Board of Scientific Advisors (BSA). |
Mission Statement Organization Staff Listing Contact Us DEA Internet DEA Intranet (NIH Access Only) Extramural Glossary DEA Annual Reports |
Division of Extramural Activities National Cancer Institute 9609 Medical Center Drive West Tower, 7th Floor Rockville, MD 20850 Bethesda, MD 20892-9750 (US Postal Address) |
DEA Annual Reports | |
---|---|
2015 | The RAS Initiative - The RAS family of oncogenes were the first oncogenes identified in human cancer cell DNA in 1981. Activating mutations in RAS genes, in particular KRAS, are observed in about 35 percent of lung adenocarcinomas and more than 90 percent of pancreatic cancers. |
2014 | Molecular Analysis for Therapy Choice (NCI-Match): A Novel Clinical Trial - The goal of NCI-MATCH is to provide clinical evidence that a drug targeting a particular molecular profile may also be effective in the treatment of more than one tumor type. |
2013 | A Precision Medicine Research Strategy - To Integrate a Taxonomic Classification of Cancer and Translate it into the Clinic. The concept that developed, that of Precision Medicine, includes four basic premises; Information Commons, Knowledge Network, Taxonomic Classifiers, and Precision Medicine. |
2012 | Molecular Diagnosis of Lymphoid Malignancies - Diffuse large B cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphona is iagnosed in more than 20,000 individuals per year in the United States. |
2011 | Deciphering the Complexity of Drug Resistance in Cancer - Cellular and molecular approaches to the study of multidrug resistance in cancer. |
2010 | Personalized Immunotherapy - Identify the Cancer Antigen and Create the Anti-Tumor T Cell |
...more DEA Annual Reports |